Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05140252 · ClinicalTrials.gov registry record · NA

Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid

A NA study of Breast Cancer, sponsored by University of Michigan Rogel Cancer Center.

Completed
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT05140252 is a NA study of Breast Cancer that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 22 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05140252, a NA study of Breast Cancer, has completed, sponsored by University of Michigan Rogel Cancer Center.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to learn whether participants find a patient guide to breast cancer treatment decisions acceptable and appropriate for use.

Conditions Studied

Interventions

  • BEHAVIORAL Breast cancer decision aid

Study Locations (1)

Michigan

  • University of Michigan Rogel Cancer Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2022-05-12
Est. Completion 2023-09-14
Phase NA

What the Registry Record Tells You About NCT05140252

The ClinicalTrials.gov registry entry for NCT05140252 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Breast cancer decision aid is the first listed.

NCT05140252 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT05140252 about?

NCT05140252 is a clinical study titled "Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid". The aim of this study is to learn whether participants find a patient guide to breast cancer treatment decisions acceptable and appropriate for use.

What is the current status of trial NCT05140252?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2022-05-12. Estimated completion is 2023-09-14.

What conditions does trial NCT05140252 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05140252?

The interventions under investigation include: Breast cancer decision aid (BEHAVIORAL).

Who is sponsoring clinical trial NCT05140252?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05140252 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.